Healthcare of Ontario Pension Plan Trust Fund Trims Holdings in Xeris Biopharma Holdings, Inc. $XERS

by · The Cerbat Gem

Healthcare of Ontario Pension Plan Trust Fund lowered its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 13.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 464,084 shares of the company’s stock after selling 73,399 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 0.27% of Xeris Biopharma worth $2,692,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at $25,000. KBC Group NV acquired a new stake in shares of Xeris Biopharma during the first quarter worth about $27,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in Xeris Biopharma by 179.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after acquiring an additional 5,000 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Xeris Biopharma

In other news, insider Steven Pieper sold 27,600 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the transaction, the insider directly owned 1,366,053 shares of the company’s stock, valued at approximately $11,638,771.56. This represents a 1.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dawn Halkuff sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director directly owned 95,000 shares of the company’s stock, valued at $578,550. This represents a 17.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 234,833 shares of company stock worth $1,742,622 in the last three months. 4.35% of the stock is currently owned by corporate insiders.

Xeris Biopharma Stock Down 4.0%

Shares of NASDAQ:XERS opened at $8.08 on Friday. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 134.67 and a beta of 0.62. The firm’s 50-day simple moving average is $7.51 and its 200-day simple moving average is $6.79. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.87 and a fifty-two week high of $10.08.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Read Our Latest Research Report on XERS

Xeris Biopharma Profile

(Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

Featured Articles

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report).